4.5 Article

Patients' preferences for headache acute and preventive treatment

期刊

JOURNAL OF HEADACHE AND PAIN
卷 18, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s10194-017-0813-3

关键词

Migraine; Tension-type headache; Cluster headache; Neurostimulation; Monoclonal antibodies; Patient-centeredness; Equity of healthcare; Nocebo

资金

  1. Allergan
  2. Amgen
  3. Biogen
  4. Brain Research
  5. GammaCore
  6. Genesis Pharma
  7. Eli Lily
  8. Merck-Serono
  9. Novatis
  10. Roche
  11. Sanofi-Genzyme
  12. Teva-Specifar
  13. Biogen-Genesis
  14. Elpen
  15. Pharmathen
  16. UCB
  17. Bayer
  18. Pfeizer
  19. Novartis
  20. Allergan Hellas
  21. Brain Therapeutics (Greece)

向作者/读者索取更多资源

Background: We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. Methods: Questionnaires from 514 outpatients naive to neurostimulation and monoclonal antibodies were collected. Results: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. Conclusion: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据